Related Experiment Videos
Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2
Abstract:
A trypsin-resistant mutant of Sendai virus, TR-2, which could be activated by chymotrypsin but not by trypsin or the protease present in mouse lung, was inoculated intranasally into mice after being activated in vitro. TR-2 hardly brought about clinical illness or lung lesions in mice; the protease present in the lung could not activate the progeny virus, and the infection terminated after one-step replication. Nevertheless, the immunoglobulin A antibody against wild-type Sendai virus was produced in the respiratory tracts as well as the serum immunoglobulin G antibody, and the mice were protected from the challenge of the wild-type Sendai virus. On the basis of these results, TR-2 may provide a new model of live vaccine for paramyxoviruses; its availability as a live vaccine is also discussed.
Insights
A novel trypsin-resistant Sendai virus mutant (TR-2) induced immunity without causing illness in mice. This paramyxovirus research suggests TR-2 could be a potential live vaccine candidate.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Sendai virus (paramyxovirus) infections can cause significant respiratory illness.
- Developing safe and effective live virus vaccines is crucial for controlling viral infections.
Purpose of the Study:
- To evaluate the potential of a trypsin-resistant Sendai virus mutant (TR-2) as a live vaccine candidate.
- To assess the immunogenicity and protective efficacy of TR-2 in a mouse model.
Main Methods:
- In vitro activation of TR-2 with chymotrypsin.
- Intranasal inoculation of activated TR-2 into mice.
- Assessment of clinical signs, lung lesions, viral replication, and antibody responses (IgA and IgG).
- Challenge with wild-type Sendai virus to evaluate protection.
Main Results:
- TR-2 showed resistance to trypsin and mouse lung protease, limiting its replication.
- Infection with TR-2 did not cause significant clinical illness or lung lesions.
- TR-2 induced both respiratory tract IgA and serum IgG antibodies against wild-type Sendai virus.
- Mice vaccinated with TR-2 were protected against challenge with wild-type Sendai virus.
Conclusions:
- TR-2 serves as a promising live vaccine model for paramyxoviruses.
- The limited replication and induction of protective immunity suggest TR-2's potential as a safe and effective live vaccine.